Agenus Inc secured up to $340 million through an oversubscribed private placement to advance its immunotherapy combination BOT+BAL for microsatellite-stable colon cancer. The funds will support the ROBBIN Phase 3 trial, targeting high-risk Stage II and III patients, with the goal of improving event-free survival compared to standard care. The trial, aligned with FDA guidelines, plans to enroll 850 patients globally, with initial dosing expected in early 2027 and interim results by late 2027. This financing is expected to sustain the company’s development efforts through 2031, addressing a US market opportunity exceeding $7 billion with no new curative treatments in over 20 years.
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
ARCpoint Inc. announced it will likely miss the July 29, 2026 deadline to file its annual financial statements and related reports due to a lack of funds to pay auditors. The company has applied for a Management Cease Trade Order (MCTO) and awaits ap...
The Rosen Law Firm is investigating potential securities claims against Putnam Investment Management, LLC, alleging that the company may have provided misleading business information to investors. Investors who purchased Putnam stock-based mutual fun...
Following a five-year antitrust lawsuit by Epic Games, Google will let Android users in the US download third-party apps directly from the Google Play Store starting July 22. This change comes after a court ruling that found Google's Play Store pract...
Ondo Global Markets reached $1 billion in total value locked (TVL) for tokenized stocks by May 2026, with projections to hit $5 billion by year-end. USDC, Circle's stablecoin, is the preferred settlement currency for these tokenized equities, favored...
